Cerenome signs in-network deal with Blue Cross Blue Shield of Michigan for CNSide test

• Cerenome signed an in-network provider agreement with Blue Cross Blue Shield of Michigan for its CNSide CSF tumor cell enumeration assay.
• Contract took effect Sept. 1, 2026; BCBSM serves about 5 million commercial and Medicare Advantage members.
• Agreement lifts CNSide contracted reimbursement coverage to about 158 million commercial and Medicare Advantage covered lives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerenome Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220730PRIMZONEFULLFEED9831057) on September 22, 2026, and is solely responsible for the information contained therein.